Peter McKay, MD
Ophthalmology · Norwich, CTNPI 1235163361
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 104 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $976 and has fallen 70.9% since, to $284 in 2025.
Across 104 payments — averaging $28.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$684
- Alcon$590
- Kala Pharmaceuticals, Inc.$217
- Novartis$193
- Amgen$164
- Sun Pharmaceutical Industries Inc.$146
- plus $975 from 17 others
What the payments were for
- Food & beverage$2,88697%
- Gifts$843%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 17 | $684 |
| Alcon | 14 | $590 |
| Kala Pharmaceuticals, Inc. | 11 | $217 |
| Novartis | 10 | $193 |
| Amgen(2 entities) | 9 | $164 |
| Sun Pharmaceutical Industries Inc. | 7 | $146 |
| Sight Sciences, Inc. | 2 | $144 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $136 |
| Bausch & Lomb Americas Inc. | 2 | $118 |
| Hoffmann-la Roche Limited | 1 | $109 |
| Oyster Point Pharma, Inc. | 4 | $84 |
| Dompe US, Inc. | 3 | $73 |
| Ocular Therapeutix, Inc. | 4 | $68 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Shire North American Group Inc | 2 | $36 |
| Astellas Pharma US Inc | 1 | $36 |
| Tarsus Pharmaceuticals, Inc. | 1 | $27 |
| Aerie Pharmaceuticals, Inc. | 2 | $25 |
| Harrow Eye, LLC | 1 | $21 |
| GSK | 1 | $19 |
| Omeros Corporation | 1 | $16 |
| Eyevance Pharmaceuticals LLC | 1 | $12 |
| Vyera Pharmaceuticals, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,970 in reported general payments places this provider in the 80th percentile of 279 ophthalmology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 85 | $110,001 |
| XiidraLifitegrast | 41 | $66,005 |
| LumiganBimatoprost | 92 | $60,692 |
| Cyclosporine | 55 | $31,227 |
| AlrexLoteprednol Etabonate | 23 | $22,731 |
| Prednisolone Acetate | 412 | $13,095 |
| Azelastine Hcl | 321 | $12,998 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 32 | $11,069 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 69 | $9,666 |
| CombiganBrimonidine Tartrate/Timolol | 24 | $9,059 |
| Travoprost | 52 | $8,852 |
| Loteprednol Etabonate | 21 | $8,103 |
| Ketorolac Tromethamine | 364 | $6,327 |
| Latanoprost | 284 | $3,855 |
| Bepotastine Besilate | 14 | $3,507 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $684 | $179,752201 claims |
| Bausch & Lomb Americas Inc.Xiidra | $118 | $66,00541 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCAlrex, Loteprednol Etabonate, Lotemax Sm | $136 | $33,50455 claims |
| AlconSimbrinza | $590 | $11,06932 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 279 ophthalmology providers in Connecticut.
Other ophthalmology in Norwich
- Anish ShahNorwich$38K
- John HuangHartford$267K
- Amir CohenNew Haven$266K
- James MurphyHamden$176K
- James TalbotNew Canaan$47K
- Paul KangNew Haven$40K
- Michael KovalFarmington$35K
- Scott SpectorNorwalk$23K
- Madina FalconeFarmington$23K
- Flora LevinBridgeport$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.